Indoramin

{{Drugbox | Verifiedfields = changed | verifiedrevid = 461936008 | IUPAC_name = N-{1-[2-(1H-indol-3-yl)ethyl]piperidin-4-yl}benzamide | image = Indoramin_svg.png

| tradename = | Drugs.com = International Drug Names | pregnancy_AU = | pregnancy_US = | pregnancy_category = | legal_AU = | legal_UK = | legal_US = | legal_status = | routes_of_administration =

| bioavailability = | protein_bound = | metabolism = | elimination_half-life = | excretion =

| CAS_number_Ref =  ^N | CAS_number = 26844-12-2 | ATC_prefix = C02 | ATC_suffix = CA02 | PubChem = 33625 | IUPHAR_ligand = 501 | DrugBank_Ref =  ^Y | DrugBank = | ChemSpiderID_Ref =  ^Y | ChemSpiderID = 31014 | UNII_Ref =  ^Y | UNII = 0Z802HMY7H | KEGG_Ref =  ^Y | KEGG = D04531 | ChEMBL_Ref =  ^Y | ChEMBL = 279516

| C=22 | H=25 | N=3 | O=1 | molecular_weight = 347.454 g/mol | smiles = O=C(c1ccccc1)NC4CCN(CCc3c2ccccc2nc3)CC4 | InChI = 1/C22H25N3O/c26-22(17-6-2-1-3-7-17)24-19-11-14-25(15-12-19)13-10-18-16-23-21-9-5-4-8-20(18)21/h1-9,16,19,23H,10-15H2,(H,24,26) | InChIKey = JXZZEXZZKAWDSP-UHFFFAOYAC | StdInChI_Ref =  ^Y | StdInChI = 1S/C22H25N3O/c26-22(17-6-2-1-3-7-17)24-19-11-14-25(15-12-19)13-10-18-16-23-21-9-5-4-8-20(18)21/h1-9,16,19,23H,10-15H2,(H,24,26) | StdInChIKey_Ref =  ^Y | StdInChIKey = JXZZEXZZKAWDSP-UHFFFAOYSA-N }}

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Indoramin (trade names Baratol and Doralese) is a piperidine antiadrenergic agent.

It is an alpha-1 selective adrenoceptor antagonist^[1] with direct myocardial depression action; therefore, it results in no reflex tachycardia. It is also used in benign prostatic hyperplasia (BPH).^[2]

It is commonly synthesized from tryptophol.^[3]

Indoramin is commonly prescribed as 20mg tablets when used in BPH.^[4]

Drowsiness, dizziness, dry mouth, nasal congestion, headache, fatigue, weight gain, hypotension, postural hypotension, depression, problems with ejaculation, diarrhoea, nausea, increased need to pass urine, and palpitations.^[5]